Business News

Argenx SE Reports Positive Data from Study


Biotechnology company Argenx SE said its abstract covering the data from its phase Ib study of ARGX-111 in patients with advanced cancers was selected as part of the Best of ASCO program at the 3rd Singapore Society of Oncology Annual Scientific Meeting in Singapore.

The company said the new data from the study continue to show evidence of anti-tumor activity with ARGX-111 at all dose levels and across different indications. “The differentiated design of ARGX-111 to enhance killing of advanced tumor cells offers a really exciting approach to treating patients with MET-driven cancers,” said Nicolas Leupin, chief medical officer of Argenx. “These data offer a compelling path forward to further examine in a phase 2 study the activity of ARGX-111, which we are looking to strategically partner.”